IDEXX Laboratories Stock

$544.55

0.45%

Nasdaq, Jul 07, 08:12 pm CET

ISIN

US45168D1046

Symbol

IDXX

Reports

Quarter | Annual

Index

NASDAQ-100, S&P 500

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

IDEXX Laboratories Stock price

$547.01

+212.25 63.40% 5Y

Nasdaq, Closing price Thu, Jul 03 2025

+4.30 0.79%

ISIN

US45168D1046

Symbol

IDXX

Reports

Quarter | Annual

Index

NASDAQ-100, S&P 500

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$44.0b

Enterprise Value

$44.8b

Net debt

$776.3m

Cash

$164.0m

Shares outstanding

80.7m

Valuation (TTM | estimate)

P/E

50.1 | 44.1

P/S

11.2 | 10.4

EV/Sales

11.4 | 10.6

EV/FCF

53.4

P/B

30.5

Financial Health

Equity Ratio

48.4%

Return on Equity

55.7%

ROCE

55.2%

ROIC

32.7%

Debt/Equity

0.6

Financials (TTM | estimate)

Revenue

$3.9b | $4.2b

EBITDA

$1.3b | $1.5b

EBIT

$1.1b | $1.3b

Net Income

$895.0m | $1.0b

Free Cash Flow

$837.7m

Growth (TTM | estimate)

Revenue

5.6% | 8.3%

EBITDA

3.9% | 16.9%

EBIT

2.7% | -

Net Income

3.3% | 12.8%

Free Cash Flow

5.1%

EPS

$10.9

FCF per Share

$10.4

Short interest

4.1%

Employees

11k

Rev per Employee

$350.0k

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

IDEXX Laboratories Stock Analysis

Unlock Scores for Free

20 Analysts have issued a IDEXX Laboratories forecast:

13x Buy

65%

7x Hold

35%

More details on Analyst Estimates Including Price Targets

20 Analysts have issued a IDEXX Laboratories forecast:

Buy

65%

Hold

35%

Analyst Estimates with Stock Price Targets

Financial data from IDEXX Laboratories

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	3,932 3,932	6% 6% 100%
- Direct Costs	1,523 1,523	3% 3% 39%
Gross Profit	2,409 2,409	8% 8% 61%
- Selling and Administrative Expenses	1,037 1,037	12% 12% 26%
- Research and Development Expense	226 226	14% 14% 6%
EBITDA	1,280 1,280	4% 4% 33%
- Depreciation and Amortization	134 134	15% 15% 3%
EBIT (Operating Income) EBIT	1,146 1,146	3% 3% 29%
Net Profit	895 895	3% 3% 23%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

IDEXX Laboratories Stock News

Neutral

Business Wire

●

13 days ago

IDEXX Laboratories to Release 2025 Second Quarter Financial Results

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 second quarter financial results for Monday, August 4, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. EDT on that day. Individuals can access a live webcast of the conference cal...

Neutral

PRNewsWire

●

about one month ago

Third Expansion of IDEXX's Catalyst Platform in Under a Year Delivers Critical Insights to Veterinarians Evaluating Canine Patients for Endocrine Disorders

The Catalyst ® Cortisol Test provides veterinarians with real-time critical insights when evaluating dogs for Addison's disease and Cushing's syndrome WESTBROOK, Maine , June 5, 2025 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the launch of the Catalyst® Cortisol Test, which measures real-time quantitative cortisol conce...

Neutral

Seeking Alpha

●

about 2 months ago

IDEXX Laboratories: Growth Remains Despite Weak Clinical Visits

IDEXX Laboratories, Inc. delivered strong Q1 FY25 results with 4.7% organic revenue and 7% adjusted EPS growth, despite weak US clinical visits. I see catalysts ahead: potential U.S. tax cuts, normalization of consumer spending, and robust pricing power supporting profit growth. Management guides for 6%-9% organic revenue and 8%-12% adjusted EPS growth in FY25; I model 8.2% revenue growth and m...

More IDEXX Laboratories News

Company Profile

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: CAG, Water, LPD, and Other. The CAG segment develops, designs, manufactures, and distributes products and performs services for veterinarians and the biomedical analytics market, primarily related to diagnostics and information management. The Water segment develops, designs, manufactures, and distributes a range of products used in the detection of various microbiological parameters in water. The LPD segment develops, designs, manufactures, and distributes diagnostic tests and related instrumentation and performs services, which are used to manage the health status of livestock and poultry, to improve producer, and to ensure the quality and safety of milk and food. The Other operating segment combines and presents products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983 and is headquartered in Westbrook, ME.

Head office	United States
CEO	Jonathan Mazelsky
Employees	11,000
Founded	1983
Website	www.idexx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now